NASDAQ:PRXL - PAREXEL International Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$88.08 0.00 (0.00 %)
(As of 08/16/2018 04:00 PM ET)
Previous Close$88.08
Today's RangeN/A
52-Week Range$51.16 - $88.10
VolumeN/A
Average Volume1.04 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
PAREXEL International logoPAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries. Its segments include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI). The CRS segment includes various phases of clinical research from first-in-man trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies, following approval by the presiding regulatory body. The PC segment provides technical expertise and advice in areas, such as strategy, drug development, regulatory affairs, strategic compliance and targeted communications services in support of product launch. The Company's PI segment provides information technology solutions.

Receive PRXL News and Ratings via Email

Sign-up to receive the latest news and ratings for PRXL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryLife Sciences Tools & Services
SectorN/A
SymbolNASDAQ:PRXL
CUSIP69946210
Phone+1-781-4879900

Debt

Debt-to-Equity Ratio1.01
Current Ratio1.45
Quick Ratio1.45

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins4.62%
Return on Equity19.95%
Return on Assets5.29%

Miscellaneous

Employees18,900
Outstanding Shares51,120,000
Market Cap$0.00

PAREXEL International (NASDAQ:PRXL) Frequently Asked Questions

What is PAREXEL International's stock symbol?

PAREXEL International trades on the NASDAQ under the ticker symbol "PRXL."

How were PAREXEL International's earnings last quarter?

PAREXEL International Co. (NASDAQ:PRXL) issued its earnings results on Wednesday, October, 26th. The medical research company reported $0.76 EPS for the quarter, missing analysts' consensus estimates of $0.86 by $0.10. The medical research company had revenue of $500.90 million for the quarter, compared to analyst estimates of $525.15 million. PAREXEL International had a return on equity of 19.95% and a net margin of 4.62%. The business's revenue for the quarter was down 2.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.70 EPS. View PAREXEL International's Earnings History.

Who are PAREXEL International's key executives?

PAREXEL International's management team includes the folowing people:
  • Josef H. von Rickenbach, Chairman of the Board, Chief Executive Officer
  • Mark A. Goldberg M.D., President, Chief Operating Officer
  • Simon Harford, Chief Financial Officer, Senior Vice President
  • , Bio & Compensation - 
  • Xavier AB Flinois, President - PAREXEL Informatics
  • Michelle Graham, Chief Human Resource Officer, Senior Vice President
  • Sybrand Pretorius M.D., Senior Vice President, Chief Scientific Officer
  • Douglas Alexander Batt, Senior Vice President, General Counsel, Secretary
  • Roland Andersson Ph.d., Senior Vice President - Clinical Research Services
  • Christian Dreger Ph.D., Senior Vice President - Parexel Access and Parexel Consulting
  • , Bio & Compensation - 
  • David J. Godwin, Senior Vice President-Global Business

Has PAREXEL International been receiving favorable news coverage?

Press coverage about PRXL stock has been trending somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PAREXEL International earned a news and rumor sentiment score of 0.21 on Accern's scale. They also gave news headlines about the medical research company an impact score of 47.40 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for PAREXEL International.

How do I buy shares of PAREXEL International?

Shares of PRXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PAREXEL International's stock price today?

One share of PRXL stock can currently be purchased for approximately $88.08.

How can I contact PAREXEL International?

PAREXEL International's mailing address is 195 West St, WALTHAM, MA 02451-1111, United States. The medical research company can be reached via phone at +1-781-4879900.


MarketBeat Community Rating for PAREXEL International (NASDAQ PRXL)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  337 (Vote Outperform)
Underperform Votes:  459 (Vote Underperform)
Total Votes:  796
MarketBeat's community ratings are surveys of what our community members think about PAREXEL International and other stocks. Vote "Outperform" if you believe PRXL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRXL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.